Summary : This figure illustrates the type classification of aortic dissections according to the Stanford system, showing three anatomical variants: Stanford Type A, Stanford Type B, and nonA-nonB dissection, with clear visualizations of the affected aortic segments. illustration: # Aortic Dissection Types : • Three labeled anatomical diagrams of the aorta, each showing a different type of aortic dissection. • Labels above each aorta: "STANFORD TYPE A", "STANFORD TYPE B", and "nonA-nonB DISSECTION". ## Stanford Type A : • Dissection involves the ascending aorta and extends beyond the aortic arch. • The false lumen (depicted as a split in the aortic wall) is present from the ascending aorta through the arch and into the descending aorta. ## Stanford Type B : • Dissection starts distal to the left subclavian artery, involving only the descending aorta. • The ascending aorta and arch are not involved. ## nonA-nonB Dissection : • Dissection involves the aortic arch but does not extend into the ascending aorta. • The false lumen is present in the arch and descending aorta, sparing the ascending aorta. # Scene Overview : • All diagrams are oriented with the aortic root at the top and the abdominal aorta at the bottom. • The aortic branches (brachiocephalic, left common carotid, left subclavian) are visible at the top of each diagram. • The false lumen is shown as a darker inner channel within the aortic wall. # Technical Details : • No scale bar or magnification is provided. • The diagrams use red and orange hues to differentiate the true and false lumens. # Spatial Relationships : • The three diagrams are aligned side-by-side for direct comparison. • The extent and location of the dissection vary between the types, highlighting the anatomical differences. # Analysis : • The figure visually distinguishes the three main anatomical patterns of aortic dissection. • Stanford Type A involves the ascending aorta, Stanford Type B is limited to the descending aorta, and nonA-nonB involves the arch without the ascending aorta. • This classification is critical for clinical decision-making and management of aortic dissections.

An educational infographic titled 'Types of cancer nanomedicine' providing a categorical classification of drug delivery systems. The diagram is organized hierarchically, branching into five primary categories of nanoparticles: 1) Liposome-based, illustrated as bilayered spherical vesicles; 2) Metal/metal oxide-based, depicted as solid inorganic spheres (e.g., gold or iron oxide); 3) Polymer/lipid-based, showing complex structures including lipid bilayers and polymer chains; 4) Polymeric micelle-based, represented as amphiphilic starburst arrangements with hydrophobic cores and hydrophilic shells; and 5) Conjugate-based, shown as small molecules attached to targeting ligands or polymers. The visual provides a fundamental overview of nanotechnology applied to oncology, focusing on diverse vehicle morphologies used to enhance drug solubility, prolong circulation, and improve targeted delivery to tumor sites. This classification is essential for understanding the pharmacological differences between approved nanodrugs and those in clinical development.

Educational flowchart and conceptual diagram illustrating the three primary domains of machine learning (ML) applicable to precision medicine, clinical diagnostics, and biomarker identification. The top level categorizes ML into Supervised Learning (model training with labeled data), Unsupervised Learning (model training with unlabeled data), and Reinforcement Learning (iterative learning via environmental feedback). Under Supervised Learning, two sub-types are shown: 'Classification,' depicting data separated into discrete categories (red triangles vs. blue dots) with a decision boundary, and 'Regression,' showing a continuous relationship with a linear trend line. Under Unsupervised Learning, 'Clustering' demonstrates the grouping of ambiguous data into distinct clusters (red, green, and blue dots) without prior labels. Reinforcement Learning is represented by a feedback loop between a 'Model Agent' and its 'Environment' involving actions, states, and feedback. Yellow stars throughout the diagram represent new, incoming data points (e.g., a patient's clinical profile) being processed or predicted by the trained models. This visual serves as a foundational guide for understanding how AI is integrated into clinical research for patient stratification and therapeutic decision-making.

A technical four-step schematic illustrating the fabrication of a surface plasmon resonance (SPR) biosensor for cardiac Troponin I (cTnI) detection. Step 1: Formation of a self-assembled monolayer (SAM) of 11-mercaptoundecanoic acid (MUDA) on a bare gold (Au) sensor chip via sulfur (S) bonding. Step 2: Surface activation using EDC/NHS (N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide/N-hydroxysuccinimide) amine coupling chemistry, showing the transition from carboxyl groups to activated NHS esters. Step 3: Immobilization of high-affinity molecularly imprinted polymer (MIP) particles, depicted as yellow crescent structures covalently attached to the surface. Step 4: Affinity-based target binding, where white irregularly shaped molecules (representing cTnI) bind specifically into the complementary cavities of the immobilized MIPs. This diagram demonstrates the principles of biomimetic sensor development, surface functionalization, and clinical biomarker detection for cardiovascular diagnostics.

<table> <tr> <th>Grading</th> <th>Management</th> </tr> <tr> <td>G1: Abnormal cardiac biomarker testing without symptoms and with no ECG abnormalities</td> <td>All grades warrant workup and intervention, given the potential for cardiac compromise.<br> Hold ICPI for G1 elevated troponin^a and recheck troponin 6 hours later. May consider resuming once normalized or if believed not to be related to ICPI.<br> Hold ICPI and discontinue for ≥ G2.</td> </tr> <tr> <td>G2: Abnormal cardiac biomarker testing with mild symptoms or new ECG abnormalities without conduction delay</td> <td>For patients with grade ≥ 2, early (ie, within 24 hours) initiation of high-dose corticosteroids (1-2 mg/kg/d of prednisone, oral or IV depending on symptoms) should be considered as it is likely to be beneficial without adverse effects.</td> </tr> <tr> <td>G3: Abnormal cardiac biomarker testing with either moderate symptoms or new conduction delay</td> <td>Admit patient for cardiology consultation.<br> Management of cardiac symptoms according to ACC/AHA guidelines and with guidance from cardiology.<br> Immediate transfer to a coronary care unit should be considered for patients with elevated troponin or conduction abnormalities.<br> For new conduction delay, consider a pacemaker.</td> </tr> <tr> <td>G4: Moderate to severe decompensation, IV medication or intervention required, life-threatening conditions</td> <td>In patients without an immediate response to high-dose corticosteroids, consider early institution of cardiac transplant rejection doses of corticosteroids (methylprednisolone 1 g every day) and the addition of either mycophenolate, infliximab, or antithymocyte globulin.²¹⁰ Consider abatacept (costimulatory molecule blockade) or alemtuzumab (CD52 blockade) as additional immunosuppression in life-threatening cases.^211,212</td> </tr> </table>

CA-125 in Ovarian Cancer — II This slide presents CA-125 as a biomarker for ovarian cancer in a text-based educational format rather than a radiologic image. The primary subject is CA-125 (MUC16), a serum biomarker whose levels correlate with tumor burden and stage in ovarian malignancy. Key points include that CA-125 elevation occurs in roughly half of patients with Stage I disease, about 90% of Stage II disease, and more than 90% with Stage III/IV disease. The slide notes a commonly used cut‑off around 35 kU/L for normal versus abnormal, and that a higher preoperative value (approximately 65 kU/L vs >65 kU/L) is associated with differential 5-year survival. Additional statements emphasize that CA-125 is useful for detecting residual disease after initial therapy and for monitoring recurrence and metastasis. The marker, however, cannot be used to distinguish ovarian cancer from other malignancies and may be elevated in benign gynecologic conditions or inflammatory states. Clinically, CA-125 informs staging, prognosis, treatment response, and surveillance and is typically interpreted alongside imaging and histopathology rather than as a standalone diagnostic test. The slide serves educational, research, and clinical practice purposes in gynecologic oncology and in studies of tumor biomarkers and longitudinal patient management.

This composite educational graphic illustrates the longitudinal monitoring of a patient with ALK-positive non-small cell lung cancer (NSCLC) undergoing targeted therapy with ceritinib. Panel A is a line graph tracking serum tumor markers CEA (μg/L) and CA 125 (U/ml) over a nine-month period. It shows a rapid quantitative decline in both markers immediately following the initiation of ceritinib, which is marked by a red arrow. Panel B presents dynamic diagnostic imaging using axial CT scans at four intervals: Baseline, Partial Response (PR) after 1.5 months, Confirmed PR after 3 months, and Confirmed PR after 10 months. The lung window (top row) displays a right lung mass (red arrow) that significantly reduces in volume and density over time. The mediastinal window (bottom row) demonstrates a circumferential pericardial effusion (red arrow) at baseline that resolves nearly completely throughout the treatment course. This visual case study highlights the correlation between biochemical marker reduction and radiographic tumor regression (RECIST criteria) in oncological management.

An educational medical illustration depicting the concept of liquid biopsy and circulating tumor components within the bloodstream. The diagram utilizes a stylized artistic rendering to show a cross-section of a blood vessel in the upper right corner, containing red blood cells and emerging tumor elements. Distributed throughout the swirling, fluid-like extracellular background are various 'tumor traces' targeted in oncology diagnostics: Circulating Tumor Cells (CTCs) shown as large, irregularly shaped clusters with prominent cytoplasmic projections; smaller, spherical circulating tumor exosomes; and fragmented, thread-like structures representing circulating tumor DNA (ctDNA) and RNA (ctRNA). The illustration serves to visualize the biological basis for liquid biopsy, emphasizing how genetic material and whole cells from a primary tumor enter systemic circulation, where they can be detected using molecular tools such as Next-Generation Sequencing (NGS) and PCR for cancer monitoring and personalized treatment.

This medical infographic illustrates the clinical application of liquid biopsy in the management of lung cancer. The diagram depicts a patient with a primary lung tumor undergoing venous blood collection. The blood sample, shown in a collection tube, is analyzed for various circulating biomarkers. A central inset highlights seven key liquid biopsy components: circulating tumor cells (CTCs) as irregular dark cells; circulating tumor DNA (ctDNA) shown as double-helix strands; exosomes as membrane-bound vesicles; microRNAs (miRNA); circular RNAs (circRNA); tumor-educated platelets (TEPs); and circulating tumor vascular endothelial cells (CTECs). Four peripheral boxes describe the clinical utility of analyzing these biomarkers: early diagnosis, prognostic prediction, effective monitoring of disease progression, and precise treatment selection. This illustration serves as a summary of non-invasive diagnostic pathways, highlighting the role of liquid biopsy in capturing tumor heterogeneity and providing real-time clinical data for oncology.

This medical flowchart illustrates a research pipeline for clear cell Renal Cell Carcinoma (ccRCC) study design, encompassing patient stratification, systems biology analysis, and drug repositioning. The workflow begins with a 'TCGA/Japanese ccRCC cohort' that undergoes 'Clustering' to stratify patients into three molecular subgroups: Subtype 1 (red), Subtype 2 (green), and Subtype 3 (blue). Parallel to this, a clinical 'REOs-based biomarker' is identified. In the 'Systems biology' phase, each subtype is processed through Genome-scale Metabolic Models (GEM), visually represented as distinct node-and-link networks. These models lead to 'Drug Target' identification, shown as diverse molecular shapes for each subtype. The 'Drug repositioning' phase focuses on an 'Inhibitor' (depicted as a therapeutic capsule) targeting these clusters. Experimental validation is shown using the Caki-1 cell line in petri dishes, demonstrating biological effects such as cell cycle arrest at the G2/M phase, indicated by a circular cell cycle diagram highlighting the transition from G2 to M. This flowchart maps the translation from multi-omic patient data to targeted therapeutic validation.

This scientific illustration and flowchart describe a clinical research study design evaluating blood-based RNA biomarkers for Coronary Artery Disease (CAD). The workflow begins with a clinical photograph of a patient experiencing exertional chest pain, prompting a differential diagnosis (Coronary, Acid Reflux, Pulmonary, Neurological, or Muscular). Diagnostic pathways shown include stress tests and blood tests, leading to imaging via CT or Angiogram. Radiological images illustrate the comparison between 'Normal Arteries' and a 'Narrowed Artery' (indicated by a red arrow). The research component is depicted through a photograph of a blood sample collection and a visualization of quantitative gene expression profiling via RNAseq. The final stages involve comparing transcriptomic data from 'LOW CAD' (<20% stenosis) and 'MID+ CAD' (>20% stenosis) groups to identify unique transcripts. The diagram effectively bridges clinical presentation, diagnostic imaging (angiography), and molecular biology techniques (RNA sequencing) to define a methodology for cardiovascular biomarker discovery.

This infographic illustrates a dual-pane flowchart detailing a radiomics workflow and an associated clinical study design for oncology research. The left pane, titled 'Radiomics Workflow,' depicts the technical pipeline: starting with 'ROI imaging' showing segmented contrast-enhanced abdominal CT scans (coronal and axial views), followed by '2D imaging' which displays 3D reconstructions and surface renderings of tumor morphology, and concluding with 'Features selection' represented by LASSO regression plots and coefficient profiles. The right pane, 'Study Flowchart,' outlines the methodological framework: initial data is split into a 'Training group' and 'Validation group.' The training pipeline involves the extraction of 856 imaging features, dimensionality reduction via LASSO logistic regression, and the construction of comparative predictive models. These models compare 'CT radiomics and CT imaging' against 'multiple clinical features' (e.g., T stage, lymph vessel invasion). The final stage indicates a model 'Comparison' and subsequent 'Validation,' concluding that the CT radiomics approach demonstrates superior predictive performance for outcomes such as lymph node metastasis.